Dossier
atopic dermatitis
Coverage of atopic dermatitis in the Nexus archive.
- AbbVie is buying an eczema and asthma drug developer for almost $11 billion
AbbVie is acquiring a drug developer for nearly $11 billion in cash to gain access to zumilokibart, an experimental drug that could rival Dupixent in treating atopic dermatitis.
- STAT+: Kailera’s own ‘triple-G’ drug also looks very powerful
The FDA delayed a decision on AstraZeneca's breast cancer drug camizestrant due to advisory concerns over its trial design. Blackstone Life Sciences is investing $1.3 billion in Apogee Therapeutics for Phase 3 development of zumilokibart, a long-acting atopic dermatitis treatment. Kailera's experimental obesity drug, targeting three hormones, showed significant weight loss in a Phase 1 study.